Skip to content

Clinical trials

Trials in Kazakhstan

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Country / region: Kazakhstan Clear all

283 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20032
20051
20062
20071
20085
20095
20106
20112
20127
20137
201411
20157
201614
201713
201820
20199
202028
202130
202214
202322
202431
202522
202619

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed174
Unknown status42
Recruiting29
Active, not recruiting15
Not yet recruiting9
Enrolling by invitation5
Terminated4
Withdrawn3
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Asfendiyarov Kazakh National Medical University19
Bayer19
Astana Medical University14
Karaganda Medical University10
Nazarbayev University10
The Society of Bariatric and Metabolic Surgeons of Kazakhstan8
Columbia University7
Hoffmann-La Roche7
Kazakh Eye Research Institute7
Research Institute for Biological Safety Problems7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
COVID-1915
Obesity15
Diabetes Mellitus, Type 213
Heart Failure12
Breast Neoplasms7
Cardiovascular Diseases7
Hypertension7
Stroke6
Tuberculosis, Multidrug-Resistant6
Carcinoma, Non-Small-Cell Lung5

Trials

Showing 51 to 75 of 283. Each trial links to its page on Pharma Observatory.

183 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.